New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
07:19 EDTMDVN, ALPMYMedivation, Astellas Pharma submit sNDA for XTANDI
Astellas Pharma (ALPMY) and Medivation (MDVN) announced the submission of a supplemental New Drug Application, or sNDA, to the FDA seeking approval of XTANDI capsules for the treatment of men with metastatic castration-resistant prostate cancer, or mCRPC, who have not received chemotherapy. XTANDI is currently approved for the treatment of patients with mCRPC who have previously received docetaxel chemotherapy. The sNDA application is based on the results from the Phase 3 PREVAIL trial evaluating XTANDI as compared to placebo in more than 1,700 chemotherapy-na´ve mCRPC patients. The marketing authorization application is expected to be submitted to the European Medicines Agency later this year.
News For MDVN;ALPMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 23, 2015
10:02 EDTMDVNOn the Fly: Analyst Initiation Summary
Subscribe for More Information
09:02 EDTMDVNMedivation recent weakness a buying opportunity, says UBS
Subscribe for More Information
January 22, 2015
16:15 EDTMDVNMedivation initiated with a Sector Perform at RBC Capital
Subscribe for More Information
09:16 EDTMDVNOn The Fly: Pre-market Movers
Subscribe for More Information
07:13 EDTMDVNMedivation up 1.2% after Phase 2 TERRAIN trial achieved primary endpoint
07:12 EDTALPMY, MDVNMedivation phase 2 TERRAIN trial achieved primary endpoint
Subscribe for More Information
January 15, 2015
11:20 EDTMDVNGoldman cuts J&J to sell citing competitive pressures
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use